GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-05-25| Trials & Approvals

EU Expands Merck’s Keytruda Use on Breast Cancer

by Fujie Tham
Share To

Merck, known as MSD outside the US and Canada, announced that the European Commission has approved its flagship monoclonal antibody drug – Keytruda, as treatment after surgery for patients with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.

Triple-negative breast cancer (TNBC) does not have estrogen or progesterone receptors while also making too little or none of the HER2 protein. Because the cancer cells are not expressing these proteins, hormone therapies and drugs that target HER2 are useless, hence chemotherapy is the main systemic treatment option. Even though TNBC tends to respond well to chemotherapy initially, it also tends to recur more frequently than other breast cancers. Approximately 10-15% of patients with breast cancer are diagnosed with TNBC.

Keytruda was first cleared for breast cancer in Europe in October 2021, for use in combination with chemotherapy as first-line treatment for patients with locally recurrent unresectable or metastatic TNBC. This news is the second indication for the drug in TNBC.

Related article: Convergence, Communication and Commercialization, The Cornerstones In Emerging Regulatory Trends

 

Phase 3 KEYNOTE-522 trial

 

The EU approval came after US FDA’s approval in July last year, both were based on the Phase 3 KEYNOTE-522 study with a size of 1174 participants. Keytruda demonstrated to be better in reducing the risk of disease progression and recurrence. The main outcome measures were pathological complete response (pCR) rate and event free survival (EFS). The pCR rate, the disappearance of all invasive cancer in the breast after completion of therapy, was 63% for patients who received Keytruda in combination with chemotherapy compared with 56% for patients who received chemotherapy alone. The number of patients who experienced an EFS event was 16% and 24%, respectively.

“Triple-negative breast cancer has a high risk of recurrence within the first five years, so it’s meaningful for patients to have access to new therapies that can reduce the risk of disease progression,” said Dr. Peter Schmid, lead of Centre for Experimental Cancer Medicine, London’s Barts Cancer Institute.

Keytruda, a cancer drug that harnesses a patient’s immune system to fight tumors, is approved in dozens of indications around the world. Sales of the drug hit $17 billion last year. Beside Keytruda, GSK’s Jemperli is also a PD-L1 immunomodulator approved for subsets of patients with advanced breast cancer that has DNA mismatch repair deficiency (dMMR).

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Pharma’s Growing (R)evolution: Sustainability and Innovations Shaping the Industry
2025-01-07
Biotech Giants Behind Partnerships in Precision Therapies, Gene Editing, and ADCs
2025-01-03
The Boldest Business Matchmaking of 2024: A Look at the Top M&A Activity
2025-01-02
LATEST
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
First-of-its-Kind Diagnostic Aid Uses a Single Hair Strand to Detect Autism Risk in Babies
2025-02-06
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
Johnson & Johnson Under Fire Again as Legal Action Over Alleged Talc-Cancer Link Moves to the UK
2025-02-05
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
EVENT
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top